SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells.

Secreted protein acidic and rich in cysteine (SPARC) is an extracellular Ca(2+)-binding matricellular glycoprotein that associates with cell populations undergoing migration, morphogenesis, and differentiation. Studies on endothelial cells have established that its principal functions in vitro are counteradhesion and antiproliferation. The mechanism(s) underlying these antitumor effects is unknown. In this study, we showed that SPARC expression in ovarian cancer cells is inversely correlated with the degree of malignancy. The immunohistochemical data presented here confirmed the importance of diminished SPARC expression in ovarian cancer development. Treating human ovarian surface epithelial cells and ovarian cancer cells with SPARC revealed that as SPARC inhibits the proliferation of both normal and cancer cells, it induces apoptosis only in cancer cells. This observation indicates that down-regulation of SPARC is essential for ovarian carcinogenesis as cancer cells become sensitized to the apoptotic activity of SPARC during malignant transformation. We also showed here the first direct evidence that putative SPARC receptors are present on ovarian epithelial cells. Their levels are higher in human ovarian surface epithelial cells than cancer cells. Binding of SPARC to its receptor is likely to trigger tissue-specific signaling pathways that mediate its tumor suppressing functions. Decrease in ligand-receptor interaction by the down-regulation of SPARC and/or its receptor is essential for ovarian carcinogenesis.

[1]  Rene Devos,et al.  Identification and expression cloning of a leptin receptor, OB-R , 1995, Cell.

[2]  V. Castronovo,et al.  Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. , 1995, The American journal of pathology.

[3]  S. Mundlos,et al.  Distribution of osteonectin mRNA and protein during human embryonic and fetal development. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  K. Mann,et al.  Structure of human osteonectin based upon analysis of cDNA and genomic sequences. , 1989, Biochemistry.

[5]  M. Tessier-Lavigne,et al.  Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III , 1997, Cell.

[6]  I. Konishi,et al.  Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and HCG inhibits apoptosis of OSE cells via up‐regulation of insulin‐like growth factor‐1 , 2001, International journal of cancer.

[7]  X. Ding,et al.  SPARC (secreted protein acidic and rich in cysteine) regulates endothelial cell shape and barrier function. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Skinner,et al.  Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer , 2001, Molecular and Cellular Endocrinology.

[9]  M. Iruela-Arispe,et al.  Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[10]  E. Sage,et al.  The Ca2(+)-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Bornstein,et al.  Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. , 1984, The Journal of biological chemistry.

[12]  P. Bornstein,et al.  Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. , 1991, The Journal of biological chemistry.

[13]  M. Webber,et al.  Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. , 1999, Cancer research.

[14]  B. Hogan,et al.  Evidence from molecular cloning that SPARC, a major product of mouse embryo parietal endoderm, is related to an endothelial cell ‘culture shock’ glycoprotein of Mr 43,000. , 1986, The EMBO journal.

[15]  Y. Sheng,et al.  Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. , 2000, Cancer research.

[16]  C. Thompson,et al.  Apoptosis in the pathogenesis and treatment of disease , 1995, Science.

[17]  R. Berkowitz,et al.  Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). , 1995, Experimental cell research.

[18]  M. Colombo,et al.  Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. , 1992, Human pathology.

[19]  A. Gown,et al.  Distribution of SPARC in normal and neoplastic human tissue. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  M. Beckmann,et al.  Resistance to CD95‐mediated apoptosis in breast cancer is not due to somatic mutation of the CD95 gene , 2001 .

[21]  S. Mok,et al.  The biology of ovarian cancer. , 1998, Seminars in oncology.

[22]  M. Castellazzi,et al.  Down-regulation of the extracellular matrix protein SPARC in vSrc- and vJun-transformed chick embryo fibroblasts contributes to tumor formation in vivo , 2000, Oncogene.

[23]  R L Vessella,et al.  Differential expression of osteonectin/SPARC during human prostate cancer progression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  M. Ringuette,et al.  Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. , 1999, Gynecologic oncology.

[25]  E. Sage,et al.  SPARC (BM-40, Osteonectin) Inhibits the Mitogenic Effect of Vascular Endothelial Growth Factor on Microvascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[26]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[27]  Daniel S. Miller,et al.  Cancer incidence and mortality, 1973‐1995 , 1998 .

[28]  A. Gown,et al.  Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. , 2000, Gynecologic oncology.

[29]  T. Mikkelsen,et al.  Increased SPARC expression promotes U87 glioblastoma invasion in vitro , 1999, International Journal of Developmental Neuroscience.

[30]  P. Chambon,et al.  Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin‐3 and BM‐40/SPARC genes , 1995, International journal of cancer.

[31]  R. Berkowitz,et al.  SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. , 1996, Oncogene.

[32]  M. Young,et al.  Antisera and cDNA probes to human and certain animal model bone matrix noncollagenous proteins. , 1995, Acta orthopaedica Scandinavica. Supplementum.

[33]  E. Sage.  Secretion of SPARC by endothelial cells transformed by polyoma middle T oncogene inhibits the growth of normal endothelial cells in vitro. , 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[34]  R. Berkowitz,et al.  Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. , 1994, Gynecologic oncology.

[35]  P. Vernier,et al.  SPARC and thrombospondin genes are repressed by the c‐jun oncogene in rat embryo fibroblasts. , 1994, The EMBO journal.

[36]  O. Podhajcer,et al.  The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. , 1997, The Journal of investigative dermatology.

[37]  M. Young,et al.  Osteonectin cDNA sequence reveals potential binding regions for calcium and hydroxyapatite and shows homologies with both a basement membrane protein (SPARC) and a serine proteinase inhibitor (ovomucoid). , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  S. Rempel,et al.  SPARC: a potential diagnostic marker of invasive meningiomas. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  E. Sage,et al.  Overexpression of SPARC in stably transfected F9 cells mediates attachment and spreading in Ca(2+)-deficient medium. , 1992, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[40]  E. Sage,et al.  The biology of SPARC, a protein that modulates cell‐matrix interactions , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  R. Timpl,et al.  Cloning and complete amino acid sequences of human and murine basement membrane protein BM‐40 (SPARC, osteonectin) , 1988, FEBS letters.

[42]  B. le Bail,et al.  Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma , 1999, The Journal of pathology.

[43]  E. Sage,et al.  Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts , 1993, Journal of cellular physiology.

[44]  E. A. Everitt,et al.  SPARC, a secreted protein associated with cellular proliferation, inhibits cell spreading in vitro and exhibits Ca+2-dependent binding to the extracellular matrix , 1989, The Journal of cell biology.

[45]  P. Holland,et al.  In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization , 1987, The Journal of cell biology.

[46]  E. Sage,et al.  Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. , 1999, Molecular biology of the cell.

[47]  P. Schraml,et al.  Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. , 1998, Cancer research.

[48]  L. Hood,et al.  Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. , 1998, Cancer research.

[49]  M. Colombo,et al.  Down-regulation of SPARC/osteonectin/BM-40 expression in methylcholanthrene-induced fibrosarcomas and in Kirsten-MSV transformed fibroblasts. , 1991, European journal of cancer.

[50]  T. Springer,et al.  Modulation of Endothelial Cell Adhesion by Hevin, an Acidic Protein Associated with High Endothelial Venules (*) , 1996, The Journal of Biological Chemistry.

[51]  M. Pike,et al.  Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. , 2000, Gynecologic oncology.

[52]  O. Podhajcer,et al.  Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells , 1997, Nature Medicine.

[53]  J. M. Kim,et al.  Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. , 2001, Endocrinology.

[54]  B. Hogan,et al.  Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization , 1988, The Journal of cell biology.

[55]  M. Young,et al.  Osteonectin mRNA: distribution in normal and transformed cells. , 1986, Nucleic acids research.

[56]  E. Sage,et al.  SPARC inhibits endothelial cell adhesion but not proliferation through a tyrosine phosphorylation‐dependent pathway , 1998, Journal of cellular biochemistry.